Sapient Capital LLC Has $1.83 Million Stock Position in Liquidia Corporation $LQDA

Sapient Capital LLC lowered its position in Liquidia Corporation (NASDAQ:LQDA) by 37.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 23,000 shares of the company’s stock after selling 14,000 shares during the period. Sapient Capital LLC’s holdings in Liquidia were worth $1,834,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. NewEdge Advisors LLC bought a new stake in shares of Liquidia during the second quarter valued at approximately $25,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Liquidia in the fourth quarter valued at $25,000. Covestor Ltd grew its holdings in shares of Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after buying an additional 359 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Liquidia by 281.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock worth $83,000 after acquiring an additional 4,927 shares in the last quarter. Finally, Hurley Capital LLC raised its holdings in shares of Liquidia by 140.7% in the 4th quarter. Hurley Capital LLC now owns 5,200 shares of the company’s stock worth $179,000 after acquiring an additional 3,040 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Insider Buying and Selling

In other news, Director Stephen M. Bloch sold 242,269 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $70.43, for a total transaction of $17,063,005.67. Following the completion of the sale, the director owned 1,176,184 shares in the company, valued at $82,838,639.12. This trade represents a 17.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Paul B. Manning sold 200,000 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $63.91, for a total value of $12,782,000.00. Following the completion of the sale, the director owned 716,311 shares in the company, valued at approximately $45,779,436.01. The trade was a 21.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,806,861 shares of company stock valued at $125,814,362 over the last three months. Insiders own 25.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on LQDA shares. Bank of America reissued a “neutral” rating and set a $79.00 price objective (up from $64.00) on shares of Liquidia in a report on Monday, June 29th. Jefferies Financial Group reissued a “buy” rating and issued a $60.00 price target on shares of Liquidia in a research report on Monday, May 11th. BTIG Research lifted their price objective on shares of Liquidia from $59.00 to $109.00 and gave the stock a “buy” rating in a report on Monday, June 22nd. HC Wainwright set a $36.00 target price on shares of Liquidia in a research note on Friday, July 24th. Finally, Wells Fargo & Company raised their price target on shares of Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $86.18.

Liquidia Price Performance

Shares of NASDAQ:LQDA opened at $91.03 on Tuesday. The company has a market capitalization of $8.10 billion, a P/E ratio of 650.26 and a beta of 0.58. The company’s 50-day moving average is $77.10 and its 200 day moving average is $54.17. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. Liquidia Corporation has a fifty-two week low of $19.90 and a fifty-two week high of $92.36.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.41 by $0.11. The business had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business’s quarterly revenue was up 4187.1% on a year-over-year basis. On average, equities research analysts forecast that Liquidia Corporation will post 3.02 earnings per share for the current year.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).